Description
Piclib 125 mg Capsule, containing the active substance palbociclib, is a kinase inhibitor used for the treatment of adult patients with HR-positive, HER-2 negative advanced, or metastatic breast cancer. The medicine Palbociclib Capsule is used in combination with aromatase inhibitors as initial endocrine-based therapy in postmenopausal women or in men. Or it can be also used in combination with fulvestrant in patients with disease progression following endocrine therapy.
Dosage and Side Effects of Piclib Capsule
The recommended starting dose of Palbociclib is a 125 mg capsule once daily taken with food for 21 days followed by 7 days of treatment. Palbociclib capsules are taken orally with food in combination with an aromatase inhibitor or fulvestrant. When given with Palbociclib, the proposed dose of fulvestrant is 500 mg administered on Days 1, 15, and 29, and once monthly thereafter. Patients must take their dose of Piclib at approximately the same time each day. In case of a missed dose, an additional dose should not be taken. The very next prescribed dose should be taken at around the usual time. Palbociclib capsules should be swallowed whole (do not crush, chew, or open them prior to swallowing).
The most commonly reported PICLIB-palbociclib side effects include: infections, vomiting, neutropenia, leukopenia, fatigue, nausea, stomatitis, anemia, alopecia, diarrhea, thrombocytopenia, rash, decreased appetite, pyrexia, and asthenia.
